Bio-Rad Laboratories Inc
NYSE: BIO-B · HEALTHCARE · MEDICAL DEVICES
Updated 2026-07-30
Bio-Rad Laboratories Inc (BIO-B) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for BIO-B.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
BIO-B historical valuation range
Where current P/E sits in BIO-B's own 5Y range.
BIO-B intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Standard discounted cash flow models produce unreliable output for unprofitable or near-breakeven companies. Revenue-based multiples such as P/S and EV/Sales, combined with the historical valuation position above, give a more reliable read for this stock.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
BIO-B valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 51.56x
P/S Ratio — History
Current: 3.20x
Is BIO-B overvalued in 2026?
Bio-Rad Laboratories Inc (BIO-B) currently trades at $309.37 per share with a market capitalization of $8,279,343,000.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 41/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 51.6x, above its 5-year median of 15.7x. The PEG ratio of 1.21 points to a price that reasonably reflects expected earnings growth.
Looking at its own history, BIO-B is currently trading more expensive than 100% of the last 5Y on P/E. This places it in the 100th percentile of its historical range, a zone where forward returns have typically been muted.
A standard DCF model does not produce reliable output for BIO-B under current conditions. For unprofitable or near-breakeven companies, revenue-based multiples such as EV/Sales and historical P/S percentile are more informative than intrinsic value calculations.
Financial quality is a concern. The Piotroski F-Score of 3/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.
Bottom line: BIO-B appears richly valued on our framework, with a Smart Value Score of 41/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is BIO-B overvalued?
BIO-B scores 41/100 on our Smart Value Score (Grade D), a weak overall profile. A standard DCF is unreliable here given the profitability profile, so valuation leans on revenue-based measures like EV/Sales and the P/S percentile below.
What is BIO-B's fair value?
A standard DCF is unreliable for BIO-B given its current profitability profile. Revenue-based approaches like EV/Sales or the historical P/S percentile are more informative for this stock.
What P/E ratio does BIO-B trade at?
BIO-B trades at a P/E of 51.6x on trailing twelve-month earnings, against a 5-year median of 15.7x. P/E is what you pay per dollar of profit, and sitting above its own median means the stock is pricier than usual relative to its earnings.
Is BIO-B a buy based on valuation?
Our Smart Value rating for BIO-B is Sell, from a Smart Value Score of 41/100 that blends growth, quality, and valuation. The profile skews cautious, and a better price or clearer operating improvement would strengthen the case. This is research to inform your decision, not personalized financial advice.
How does BIO-B's valuation compare to its history?
On P/E, BIO-B sits in the 100th percentile of its own 5Y range, historically expensive relative to where it has traded. A high percentile means today's multiple is near the top of its historical band.
What is BIO-B's Smart Value Score?
BIO-B's Smart Value Score is 41/100. It is a proprietary WallStSmart metric blending growth quality, financial health, and valuation into a single 0-100 read, and scores above 75 are rare, signaling strong multi-factor alignment.